Abstract
Major aims of the 5th Central and Eastern Europe (CEE) Summit on Osteoporosis held in Bratislava, Slovakia, on 2 and 3 December 2011, were to provide participants with state-of-the-art knowledge in the fields of osteoporosis research, diagnosis, and therapy and to evaluate, compare, and discuss the very heterogeneous health care situations and related challenges in the different countries in CEE and elsewhere. The summit was attended by 70 delegates from 15 countries. State-of-the-art lectures given by international authorities on osteoporosis covered a broad spectrum of topics ranging from osteoporosis in the male population, novel therapies in osteoporosis such as cathepsin K and sclerostin inhibitors, and the implementation and use of FRAX® in CEE, to an update on denosumab for the management of osteoporosis. Workshops organized to enable the exchange of individual experiences addressed the importance and current availability of osteology training for physicians and the impact of patient training programs on therapy compliance. Furthermore, the availability of and need for standardized quality controls and therapy guidelines in different CEE countries were discussed. Finally, based on a questionnaire, a very up-to-date analysis of all participating countries regarding incidences of osteoporosis, commonly used diagnostic and therapeutic measures, the number of specialists and specialized hospitals, and differences in the reimbursement situation in the different countries was generated and presented. On the whole, the very authentic contributions and the synergistic exchange of ideas allowed the identification of both positive developments as well as still existing issues and needs in diagnosis and therapy of osteoporosis.
Similar content being viewed by others
References
Lorenc RS, Resch H (2009) Management of osteoporosis in central and eastern Europe (CEE): conclusions of the “2nd Summit on Osteoporosis-CEE”, 21–22 November 2008, Warsaw, Poland. Arch Osteoporos 4:1–8
Lakatos P, Balogh Á, Czerwinski E, Dimai HP, Hans D, Holzer G, Lorenc RS, Palicka V et al (2011) New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis-CEE”, November 2009, Budapest, Hungary. Arch Osteoporos 6:1–12
Gennari L, Bilezikian JP (2007) Osteoporosis in men. Endocrinol Metab Clin North Am 36:399–419
Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, Seeman E (2011) Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 22:2789–2798
Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 7:447–456
Binkley N, Bone H, Gilchrist N, Langdahl B, Resch H, Rodriguez-Portales J, Leung A, Lombardi A et al. (2011) Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. J Bone Miner Res 26 Suppl 1: abstract FR0453
Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S (2012) Inhibition of cathepsin k for treatment of osteoporosis. Curr Osteoporos Rep 10:73–79
Wagner ER, Zhu G, Zhang BQ, Luo Q, Shi Q, Huang E, Gao Y, Gao JL et al (2011) The therapeutic potential of the Wnt signaling pathway in bone disorders. Curr Mol Pharmacol 4:14–25
Anastasilakis AD, Polyzos SA, Toulis KA (2011) Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge. Curr Opin Endocrinol Diabetes Obes 18:383–388
Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN et al (2010) Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614–41626
McCloskey EV, Johansson H, Oden A, Kanis JA (2009) From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep 7:77–83
Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407–413
Lewiecki EM (2011) Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med 12:263–273
Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26
Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701
Dachverband Osteologie e. V (2011) DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20:55–74
Annual report 2010. International Osteoporosis Foundation. http://www.iofbonehealth.org/sites/default/files/IOF_annual_report-2010.pdf. Accessed Aug 2012
Pohlídal A, Husek P, Palicka V, Slabík D, Hill M, Matucha P (2003) Novel and traditional biomarkers of bone turnover in postmenopausal women. Clin Chem Lab Med 41:74–78
Acknowledgments
The organization of the 5th CEE Summit on Osteoporosis and the preparation of the manuscript were supported by an unrestricted educational grant of Amgen GmbH, Vienna, Austria. The following people contributed to the preparation of the manuscript: John Kanis, WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK; Cesar Libanati, MD, Research and Development, Bone Therapeutic Area, Amgen Inc, Thousand Oaks, CA, USA; Gerd Möller, MD, International Senior Medical Scientist, Amgen (Europe) GmbH, Zug, Switzerland; Vladimir Palička Charles University, School of Medicine Hradec Kralove, Osteocentre, University Hospital, Hradec Kralove, Czech Republic; Socrates Papapoulos, Department of Endocrinology & Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands; and Catalina Poiana, MD, CI Parhon National Institute of Endocrinology, Bucharest, Romania.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Payer, J., Bilezikian, J.P., Holzer, G. et al. Congress Report: 5th Central and Eastern Europe (CEE) Summit on Osteoporosis in Bratislava, 2–3 December 2011. Arch Osteoporos 8, 123 (2013). https://doi.org/10.1007/s11657-013-0123-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11657-013-0123-6